Showing 3031-3040 of 5621 results for "".
- Alcon Debuts Dailies Total1 for Astigmatism, Other Eye Care Innovations at SECO 2022https://modernod.com/news/alcon-debuts-dailies-total1-for-astigmatism-other-eye-care-innovations-at-seco-2022/2480694/
- Lighthouse Guild Opens Technology Center for People Who are Blind or Visually Impairedhttps://modernod.com/news/lighthouse-guild-opens-technology-center-for-people-who-are-blind-or-visually-impaired/2480685/Lighthouse Guild Technology Center, which offers people who are blind or visually impaired access to the latest assistive devices and state-of-the-art technology, celebrated its official opening. The Center occupies 11,000 square feet at Lighthouse Guild’s New York City headquarters and is
- EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/EyePoint Pharmaceuticals announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings more than 30 years of global regulatory affairs experience across all phases of drug development, including ophthalmic and ocular conditions. Ms. Lefebvre is su
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Tarsus Appoints José Trevejo, MD, PhD, Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/Tarsus Pharmaceuticals announced the appointment of José Trevejo, MD, PhD, as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- Pixium Vision Announces the Publication of Peer-Reviewed Clinical Data Demonstrating the Clinical Benefit of the Prima System in Dry AMD Patientshttps://modernod.com/news/pixium-vision-announces-the-publication-of-peer-reviewed-clinical-data-demonstrating-the-clinical-benefit-of-the-prima-system-in-dry-amd-patients/2480597/Pixium Vision SA announced the publication of a paper in Nature Communications outlining further data with its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophi
- Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patientshttps://modernod.com/news/nanoscope-therapeutics-announces-fda-clearance-of-ind-for-mco-010-gene-therapy-in-stargardt-macular-degeneration-patients/2480594/Nanoscope Therapeutics announced it received IND clearance from the FDA to begin a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients. “This is another important milestone for Nanoscop
- Refractive Surgery Council Reports 32% YTD Increase in Laser Vision Correction Procedure Volume over 2020https://modernod.com/news/refractive-surgery-council-reports-32-ytd-increase-in-laser-vision-correction-procedure-volume-over-2020/2480591/T